secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001842952-25-000072
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics stockholders approve reverse stock split and ratify auditor at 2025 annual meeting
--------------------------------------------------------------------------------

- 66,716,026 shares (74.37% of outstanding) present at June 12, 2025 annual meeting.
- Ratified CohnReznick LLP as auditor for FY2025 with 66,649,293 votes for, 20,039 against.
- Approved reverse stock split at ratio from 1:5 to 1:50, as determined by Board; 65,141,783 for, 1,540,542 against.
- No broker non-votes reported; both proposals were routine matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295225000072/0001842952-25-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295225000072/cntx-20250612.htm
  HTML page:      https://secwatch.observer/filing/0001842952-25-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer